These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24032526)

  • 1. Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study.
    Young WB; Bradley KC; Anjum MW; Gebeline-Myers C
    Headache; 2013 Oct; 53(9):1430-7. PubMed ID: 24032526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SumaRT/Nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study.
    Cady R; O'Carroll P; Dexter K; Freitag F; Shade CL
    Headache; 2014 Jan; 54(1):67-79. PubMed ID: 24021029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 3-month analysis of disability, quality of life, and disease course in patients with migraine.
    Raggi A; Leonardi M; Bussone G; D'Amico D
    Headache; 2013 Feb; 53(2):297-309. PubMed ID: 23094760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
    Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
    Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications.
    Cady RK; Voirin J; Farmer K; Browning R; Beach ME; Tarrasch J
    Headache; 2012 May; 52(5):749-64. PubMed ID: 22188311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
    Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
    Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.
    Buse D; Manack A; Serrano D; Reed M; Varon S; Turkel C; Lipton R
    Headache; 2012 Jan; 52(1):3-17. PubMed ID: 22106869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects.
    Young W; Shaw J; Bloom M; Gebeline-Myers C
    Headache; 2008; 48(10):1490-8. PubMed ID: 19076647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Duloxetine in the treatment of chronic migraine].
    Artemenko AR; Kurenkov AL; Nikitin SS; Filatova EG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(1):49-54. PubMed ID: 20436437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topiramate for migraine prevention in a naturalistic setting: results from an open label, flexible dose study.
    Nelles G; Delbrück A; Schulze L; Kademann B; Bornhoevd K; Schäfer S; Schäuble B;
    Headache; 2009; 49(10):1454-65. PubMed ID: 19804392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders.
    Tarlaci S
    Clin Neuropharmacol; 2009; 32(5):254-8. PubMed ID: 19667978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of duloxetine as a migraine preventive medication: possible predictors of response in a retrospective chart review.
    Taylor AP; Adelman JU; Freeman MC
    Headache; 2007 Sep; 47(8):1200-3. PubMed ID: 17883526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study.
    Krymchantowski AV; Jevoux CC
    Headache; 2011 Apr; 51(4):554-8. PubMed ID: 21457240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep disturbance and affective comorbidity among episodic migraineurs.
    Walters AB; Hamer JD; Smitherman TA
    Headache; 2014 Jan; 54(1):116-24. PubMed ID: 23808359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.